Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus

References

• Williams DF. To engineer is to create: the link between engineering and regeneration. Trends Biotechnol. 2006;24: 4–8. Epub 2005/11/18.
   PubMed Web of Science ®Google Scholar
• Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 2004;428: 487–492. Epub 2004/04/02.
   PubMed Web of Science ®Google Scholar
• Slavkin HC, Bartold PM. Challenges and potential in tissue engineering. Periodontol. 2000;2006(41): 9–15. Epub 2006/05/12.
   Google Scholar
• Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83: 835–870. Epub 2003/07/05.
   PubMed Web of Science ®Google Scholar
• Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004;79: 677–688. Epub 2004/10/27.
   PubMed Web of Science ®Google Scholar
• Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regen Med. 2013;8: 645–658. Epub 2013/09/04.
   PubMed Web of Science ®Google Scholar
• Anitua E, Nurden P, Prado R, et al. Autologous fibrin scaffolds: when platelet- and plasma-derived biomolecules meet fibrin. Biomaterials. 2019;192:440–460.
   PubMed Web of Science ®Google Scholar
• Khodakaram-Tafti A, Mehrabani D, Shaterzadeh-Yazdi H. An overview on autologous fibrin glue in bone tissue engineering of maxillofacial surgery. Dent Res J (Isfahan). 2017;14: 79–86. Epub 2017/06/07.
   PubMedGoogle Scholar
• Matras H, Braun F, Lassmann H, et al. Plasma clot welding of nerves. (Experimental report). J Maxillofac Surg. 1973;1:236–247, Epub 1973/12/01.
   PubMedGoogle Scholar
• Marx RE. Platelet-Rich Plasma (PRP): what Is PRP and what is not PRP? Implant Dent. 2001;10:225–228.
   PubMedGoogle Scholar
• Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14: 529–535. Epub 1999/08/24.
   PubMed Web of Science ®Google Scholar
• Leitner GC, Gruber R, Neumüller J, et al. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang. 2006;91:135–139. Epub 2006/08/16.
   PubMed Web of Science ®Google Scholar
• Sánchez M, Azofra J, Anitua E, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc. 2003;35:1648–1652. Epub 2003/10/03.
   PubMed Web of Science ®Google Scholar
• Leitner GC, Gruber R, Neumuller J, et al. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang. 2006;91:135–139. Epub 2006/08/16.
   PubMed Web of Science ®Google Scholar
• Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009;97:110–118. Epub 2009/04/28.
   PubMed Web of Science ®Google Scholar
• Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39:266–271.
   PubMed Web of Science ®Google Scholar
• Kushida S, Kakudo N, Morimoto N, et al. Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems. J Artif Organs. 2014;17:186–192. Epub 2014/04/22.
   PubMed Web of Science ®Google Scholar
• Magalon J, Bausset O, Serratrice N, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30:629–638. Epub 2014/04/15.
   PubMed Web of Science ®Google Scholar
• Degen RM, Bernard JA, Oliver KS, et al. Commercial separation systems designed for preparation of platelet-rich plasma yield differences in cellular composition. HSS J. 2017;13:75–80.
   PubMedGoogle Scholar
• Fitzpatrick J, Bulsara MK, McCrory PR, et al. Analysis of platelet-rich plasma extraction: variations in platelet and blood components between 4 common commercial kits. Orthop J Sports Med. 2017;5:2325967116675272. Epub 2017/02/18.
   Web of Science ®Google Scholar
• Oudelaar BW, Peerbooms JC, Huis I, et al. Concentrations of blood components in commercial platelet-rich plasma separation systems: a review of the literature. Am J Sports Med. 2019;47:479-487.
   PubMed Web of Science ®Google Scholar
• Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018;4:18–24.
   PubMed Web of Science ®Google Scholar
• Gato-Calvo L, Magalhaes J, Ruiz-Romero C, et al. Platelet-rich plasma in osteoarthritis treatment: review of current evidence. Ther Adv Chronic Dis. 2019;10:2040622319825567. Epub 2019/03/01.
   Web of Science ®Google Scholar
• Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14: S88–101. Epub 2008/05/09.
   PubMed Web of Science ®Google Scholar
• Blomquist PH. Ocular complications of systemic medications. Am J Med Sci. 2011;342: 62–69. Epub 2010/12/09.
   PubMed Web of Science ®Google Scholar
• Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2:CD009327.
   PubMed Web of Science ®Google Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6: 37–42. Epub 2014/07/09.
   PubMedGoogle Scholar
• Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93:e605–14. * Review study related to PRGF in ophthalmology published until 2015
   PubMed Web of Science ®Google Scholar
• Riestra AC, Alonso-Herreros JM, Merayo-Lloves J. Platelet rich plasma in ocular surface. Arch Soc Esp Oftalmol. 2016;91:475–490.
   PubMedGoogle Scholar
• Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol. 1975;93: 1039–1043. Epub 1975/10/01.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Shimmura S, et al. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999;106:1984–1989, Epub 1999/10/16.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol. 1999;83:390–395, Epub 1999/08/06.
   PubMed Web of Science ®Google Scholar
• Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–461. Epub 1984/04/01.
   PubMed Web of Science ®Google Scholar
• Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467.
   PubMed Web of Science ®Google Scholar
• Definition T. Classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye Workshop (2007). Ocular Surf. 2007;5:75–92.
   PubMed Web of Science ®Google Scholar
• Freire V, Andollo N, Etxebarria J, et al. In vitro effects of three blood derivatives on human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2012;53:5571–5578.
   PubMed Web of Science ®Google Scholar
• Freire V, Andollo N, Etxebarria J, et al. Corneal wound healing promoted by 3 blood derivatives: an in vitro and in vivo comparative study. Cornea. 2014;33:614–620.
   PubMed Web of Science ®Google Scholar
• Bernabei F, Roda M, Buzzi M, et al. Blood-based treatments for severe dry eye disease: the need of a consensus. J Clin Med. 2019;8:1478.
   Web of Science ®Google Scholar
• Ribeiro MVMR, VFd M, Barbosa MEFC, et al. The use of platelet rich-plasma in ophthalmology: a literature review. Rev Bras Oftalmol. 2017;76:319-324.
   Google Scholar
• Anitua E, Muruzabal F, de la Fuente M, et al. Plasma rich in growth factors for the treatment of ocular surface diseases. Curr Eye Res. 2016;41:875–882.
   PubMed Web of Science ®Google Scholar
• Anitua E, Zalduendo MM, Alkhraisat MH, et al. Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors. Ann Anat. 2013;195:461–466. Epub 2013/06/01.
   PubMed Web of Science ®Google Scholar
• Anitua E, Prado R, Troya M, et al. Implementation of a more physiological plasma rich in growth factor (PRGF) protocol: anticoagulant removal and reduction in activator concentration. Platelets 2016;27:459–466.
   PubMed Web of Science ®Google Scholar
• Anitua E, Prado R, Nurden AT, et al. Characterization of Plasma Rich in Growth Factors (PRGF): components and formulations. In: Anitua E, Cugat R, Sánchez Meditors. Platelet rich plasma in orthopaedics and sports medicine. Cham: Springer International Publishing; 2018;29–45.
   Google Scholar
• Anitua E, Zalduendo MM, Prado R, et al. Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion. J Biomed Mater Res A. 2015;103:1011–1020.
   PubMed Web of Science ®Google Scholar
• Koizumi K, Poulaki V, Doehmen S, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci. 2003;44:2184–2191. Epub 2003/04/26.
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Marin V, Montero-Julian F, et al. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24:25–29. Epub 2002/12/24.
   PubMed Web of Science ®Google Scholar
• Long EOICAM. 1: getting a grip on leukocyte adhesion. J Immunol. 2011;186: 5021–5023. Epub 2011/04/21.
   PubMed Web of Science ®Google Scholar
• Anitua E, Sanchez M, Orive G, et al. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007;28:4551–4560.
   PubMed Web of Science ®Google Scholar
• Blasetti F, Usai D, Sotgia S, et al. A protocol for microbiologically safe preparation, storage, and use of autologous serum eye-drops in low-income countries. J Infect Dev Ctries. 2015;9:55–59.
   PubMed Web of Science ®Google Scholar
• Thanathanee O, Phanphruk W, Anutarapongpan O, et al. Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases. Cornea 2013;32:1116–1119. Epub 2013/05/15.
   PubMed Web of Science ®Google Scholar
• Anitua E, Alonso R, Girbau C, et al. Antibacterial effect of plasma rich in growth factors (PRGF(R)-Endoret(R)) against Staphylococcus aureus and Staphylococcus epidermidis strains. Clin Exp Dermatol. 2012;37:652–657.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Pino A, et al. Biological stability of plasma rich in growth factors eye drops after storage of 3 months. Cornea 2013;32:1380–1386, Epub 2013/08/27.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Riestra A, et al. Preservation of biological activity of plasma and platelet-derived eye drops after their different time and temperature conditions of storage. Cornea 2015;34:1144–1148. Epub 2015/07/15.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Muruzábal F, et al. Short- and long-term stability of plasma rich in growth factors eye drops. Cornea. 2021;40:107-112;
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Riestra A, et al. Galenic validation of plasma rich in growth factors eye drops. Farm Hosp. 2019;43:45–49.
   PubMed Web of Science ®Google Scholar
• Arakawa T, Prestrelski SJ, Kenney WC, et al. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev. 2001;46:307–326. Epub 2001/03/22.
   PubMed Web of Science ®Google Scholar
• Izutsu KI. Applications of freezing and freeze-drying in pharmaceutical formulations. Adv Exp Med Biol. 2018;1081: 371–383. Epub 2018/10/06.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Alcalde I, et al. Development and optimization of freeze-dried eye drops derived from plasma rich in growth factors technology. Trans Vis Sci Technol. 2020;9:35.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Muruzabal F, et al. Stability of freeze-dried plasma rich in growth factors eye drops stored for 3 months at different temperature conditions. Eur J Ophthalmol. 2021;31:354-360.
   PubMed Web of Science ®Google Scholar
• Anitua E, Prado R, Azkargorta M, et al. High-throughput proteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome. J Tissue Eng Regen Med. 2015;9:E1–12.
   PubMed Web of Science ®Google Scholar
• Anitua E, Sanchez M, Merayo-Lloves J, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011;52:6066–6073.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Alcalde I, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Exp Eye Res. 2013;115:153–161.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Muruzabal F, et al. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res. 2015;135:118–126.
   PubMed Web of Science ®Google Scholar
• Anitua E, Zalduendo M, Troya M, et al. Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties. PLoS One. 2015;10:e0121713.
   PubMed Web of Science ®Google Scholar
• Bendinelli P, Matteucci E, Dogliotti G, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. J Cell Physiol. 2010;225:757–766.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, de la Fuente M, et al. PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model. Exp Eye Res. 2016;151:115–121.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201–211. Epub 1999/09/17.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (Baltimore, Md: 1950). 2013;190:3831–3838.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, De la Fuente M, et al. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res. 2014;119:27–34.
   PubMed Web of Science ®Google Scholar
• Anitua E, De la Fuente M, Muruzabal F, et al. Development and optimization of a personalized fibrin membrane derived from the plasma rich in growth factors technology. Exp Eye Res. 2021;203:108402. Epub 2020/12/14.
   Web of Science ®Google Scholar
• López-Paniagua M, Nieto-Miguel T, de la Mata A, et al. Consecutive expansion of limbal epithelial stem cells from a single limbal biopsy. Curr Eye Res. 2013;38:537–549.
   PubMed Web of Science ®Google Scholar
• Kolli S, Ahmad S, Lako M, et al. Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency. Stem Cells. 2010;28:597–610, Epub 2009/12/17.
   PubMed Web of Science ®Google Scholar
• Kruse FE, Tseng SC. Serum differentially modulates the clonal growth and differentiation of cultured limbal and corneal epithelium. Invest Ophthalmol Vis Sci. 1993;34: 2976–2989. Epub 1993/09/01.
   PubMed Web of Science ®Google Scholar
• Schwab IR, Johnson NT, Harkin DG. Inherent risks associated with manufacture of bioengineered ocular surface tissue. Arch Ophthalmol. 2006;124: 1734–1740. Epub 2006/12/13.
   PubMed Web of Science ®Google Scholar
• Anitua E, Prado R, Orive G. Endogenous morphogens and fibrin bioscaffolds for stem cell therapeutics. Trends Biotechnol. 2013;31: 364–374. Epub 2013/05/07.
   PubMed Web of Science ®Google Scholar
• Etxebarria J, Sanz-Lazaro S, Hernaez-Moya R, et al. Serum from plasma rich in growth factors regenerates rabbit corneas by promoting cell proliferation, migration, differentiation, adhesion and limbal stemness. Acta Ophthalmol. 2017;95:e693–e705.
   PubMed Web of Science ®Google Scholar
• Riestra AC, Vazquez N, Chacon M, et al. Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology. Ocul Surf. 2017;15:248–256.
   PubMed Web of Science ®Google Scholar
• Persinal-Medina M, Llames S, Vazquez N, et al. Xeno-free approach for the expansion of human adipose derived mesenchymal stem cells for ocular therapies. Exp Eye Res. 2021;202:108358. Epub 2020/11/15. .
   Web of Science ®Google Scholar
• Rocha GA, Acera A, Durán JA. Laser in situ keratomileusis flap necrosis after trigeminal nerve palsy. Arch Ophthalmol. 2007;125: 1423–1425. Epub 2007/10/10.
   PubMedGoogle Scholar
• López-Plandolit S, Morales MC, Freire V, et al. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 2010;29:843–848. Epub 2010/05/29.
   PubMed Web of Science ®Google Scholar
• Merayo-Lloves J, Sanchez RM, Riestra AC, et al. Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders. Ophthalmic Res. 2015;55:53–61.
   PubMed Web of Science ®Google Scholar
• Guarnieri A, Alfonso-Bartolozzi B, Ciufo G, et al. Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer. Medicine (Baltimore). 2017;96:e7000.
   PubMed Web of Science ®Google Scholar
• Guadilla AM, Balado P, Baeza A, et al. Effectiveness of topical autologous serum treatment in neurotrophic keratopathy. Archivos de la Sociedad Española de Oftalmología (English Edition). 2013;88:302–306.
   Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018;38:1193–1204.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802–812.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000;19: 644–649. Epub 2000/09/29.
   PubMed Web of Science ®Google Scholar
• López-Plandolit S, Morales MC, Freire V, et al. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea 2011;30:1312–1317. Epub 2011/10/21.
   PubMed Web of Science ®Google Scholar
• Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye. Ophthalmic Res. 2016;56:68–73.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Fernandez ML, et al. Plasma rich in growth factors for the treatment of dry eye after LASIK surgery. Ophthalmic Res. 2018;60:80–86.
   PubMed Web of Science ®Google Scholar
• Begley CG, Caffery B, Chalmers RL, et al. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea 2002;21:664–670, Epub 2002/09/28.
   PubMed Web of Science ®Google Scholar
• GN S, MH M, Gl I, et al. Health outcomes and pharmacoeconomic aspects PRGF dry eye.pdf. OFIL·ILAPHAR. 2020.
   Google Scholar
• Gagliano C, Caruso S, Napolitano G, et al. Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case-control study. Br J Ophthalmol. 2014;98:371–376. Epub 2014/01/07.
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjögren’s syndrome. Lancet 2005;366: 321–331. Epub 2005/07/26.
   PubMed Web of Science ®Google Scholar
• Theander E, Jacobsson LT. Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am. 2008;34: 935–47, viii–ix. Epub 2008/11/06.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sjogren syndrome. J Ocul Pharmacol Ther. 2017;33:391–399.
   PubMed Web of Science ®Google Scholar
• Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol. 2013;27: 215–222. Epub 2013/11/15.
   PubMedGoogle Scholar
• Allan EJ, Flowers ME, Lin MP, et al. Visual acuity and anterior segment findings in chronic graft-versus-host disease. Cornea 2011;30:1392–1397. Epub 2011/10/15.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Muruzabal F, et al. Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases. Eur J Ophthalmol. 2020;30:94–103.
   PubMed Web of Science ®Google Scholar
• Solomon A, Pires RT, Tseng SC. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology 2001;108: 449–460. Epub 2001/03/10.
   PubMed Web of Science ®Google Scholar
• Hanada K, Nishikawa N, Miyokawa N, et al. Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision. Int Ophthalmol. 2017;37:71–78. Epub 2016/04/12.
   PubMed Web of Science ®Google Scholar
• Bhandari V, Rao CL, Ganesh S, et al. Visual outcome and efficacy of conjunctival autograft, harvested from the body of pterygium in pterygium excision. Clin Ophthalmol. 2015;9:2285–2290. Epub 2015/12/15.
   PubMed Web of Science ®Google Scholar
• Rahman I, Said DG, Maharajan VS, et al. Amniotic membrane in ophthalmology: indications and limitations. Eye (Lond). 2009;23:1954–1961. Epub 2009/01/27.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders. Medicine (Baltimore). 2018;97:e0242.
   PubMed Web of Science ®Google Scholar
• Idoipe-Corta M Membrane of Plasma rich in growth factors in primary pterygium surgeries compared to amniotic membrane transplantation and conjunctival autograft: a prospective study. 2020.
   Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96: 614–618. Epub 2011/12/03.
   PubMed Web of Science ®Google Scholar
• Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80: 389–393. Epub 1996/05/01.
   PubMed Web of Science ®Google Scholar
• Monaco G, Cacioppo V, Consonni D, et al. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy. Eur J Ophthalmol. 2011;21:243–250. Epub 2010/09/28.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Fernandez ML, et al. Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. Int Med Case Rep J. 2018;11:97–103.
   PubMed Web of Science ®Google Scholar
• Antón A, Andrada MT, Mujica V, et al. Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. J Glaucoma. 2004;13:371–376. Epub 2004/09/09.
   PubMed Web of Science ®Google Scholar
• Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K. 1983;103(Pt 1): 84–88. Epub 1983/01/01.
   PubMedGoogle Scholar
• Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314–346.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Agirretxe I, Freire V, Muruzabal F, et al. Subconjunctival PRGF fibrin membrane as an adjuvant to nonpenetrating deep sclerectomy: a 2-year pilot study. Ophthalmic Res. 2018;59:45–52.
   PubMed Web of Science ®Google Scholar
• Majmudar PA, Forstot SL, Dennis RF, et al. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 2000;107:89–94. Epub 2000/01/27.
   PubMed Web of Science ®Google Scholar
• Coelho LM, Sieiro RO. Mitomycin C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy. Int Ophthalmol. 2019;39: 341–345. Epub 2018/01/18.
   PubMed Web of Science ®Google Scholar
• Morales AJ, Zadok D, Mora-Retana R, et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy. Am J Ophthalmol. 2006;142:400–404, Epub 2006/08/29.
   PubMed Web of Science ®Google Scholar
• Crawford C, Ainbinder DJ, Davis R, et al. Systemic absorption of mitomycin-C when used in refractive surgery. J Cataract Refract Surg. 2013;39:193–196. Epub 2012/11/13.
   PubMed Web of Science ®Google Scholar
• Ronald M, Sanchez-Avila EEU-B, Javier Fernández-Vega Sanz FM, et al. Plasma rich in growth factors versus Mitomycin C in PRK. (In-press). 2020.
   Google Scholar
• Bobba S, Devlin C, Di Girolamo N, et al. Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. Eye (Lond). 2018;32:1636–1643. Epub 2018/06/21.
   PubMed Web of Science ®Google Scholar
• de la Sen-Corcuera B, Montero-Iruzubieta J, Sanchez-Avila RM, et al. Plasma Rich in growth factors for the treatment of cicatrizing conjunctivitis. Clin Ophthalmol. 2020;14:1619–1627.
   PubMed Web of Science ®Google Scholar
• Sanchez Avila RM-LJ. Neurotrophic ulcer after cataract surgery: new treatment. EC Ophthalmol. 2016;3(5):359–365.
   Google Scholar
• Cejkova J, Olmiere C, Cejka C, et al. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage. Histol Histopathol. 2014;29:457–478. Epub 2013/10/10.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Uribe-Badillo E, Gonzalez CF-V, et al. Treatment of noninfectious corneal disorders with plasma rich in growth factors and regenerating agent matrix. [Manuscript Submitted for Publication]. 2020.
   Google Scholar
• Al-Mujaini A, Ganesh A, Al-Zuhaibi S. Autogenous dermis-fat orbital impant for anophthalmic socket. Sultan Qaboos Univ Med J. 2007;7: 145–148. Epub 2007/08/01.
   PubMedGoogle Scholar
• Essuman VA, Tagoe NN, Ndanu TA, et al. Dermis-fat grafts and enucleation in Ghanaian children: 5 years’ experience. Ghana Med J. 2014;48:204–207. Epub 2015/02/25.
   PubMedGoogle Scholar
• Chaparro Tapias TA, Diaz Diaz AL, Secondi R, et al. Platelet-rich plasma to rescue an ulcerated orbital dermal fat graft. Eur J Ophthalmol. 2019;29:654–658.
   PubMed Web of Science ®Google Scholar
• Bautista-Llamas MJ, Sánchez-González MC, López-Izquierdo I, et al. Complications and explantation reasons in Intracorneal Ring Segments (ICRS) implantation: a systematic review. J Refract Surg. 2019;35:740–747, Epub 2019/11/12.
   PubMed Web of Science ®Google Scholar
• Ibares-Frias L, Gallego-Munoz P, Orive G, et al. Potential effect of plasma rich in growth factors-endoret in stromal wound healing in additive surgery. Ophthalmic Res. 2020;63:203–212.
   PubMed Web of Science ®Google Scholar
• Suárez-Barrio C, Etxebarria J, Hernáez-Moya R, et al. Hyaluronic acid combined with serum rich in growth factors in corneal epithelial defects. Int J Mol Sci 2019;20:1655. Epub 2019/04/17.
   Web of Science ®Google Scholar
• Bowes Rickman C, Farsiu S, Toth CA, et al. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest Ophthalmol Vis Sci. 2013;54:Orsf68–80. Epub 2013/12/18.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–1452. Epub 2004/07/03.
   PubMed Web of Science ®Google Scholar
• Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115–134. Epub 2000/10/18.
   PubMed Web of Science ®Google Scholar
• Takayama K, Kaneko H, Kataoka K, et al. Nuclear factor (Erythroid-Derived)-related Factor 2-associated retinal pigment epithelial cell protection under blue light-induced oxidative stress. Oxid Med Cell Longev. 2016;2016:8694641.
   PubMed Web of Science ®Google Scholar
• Tao JX, Zhou WC, Zhu XG. Mitochondria as potential targets and initiators of the blue light hazard to the retina. Oxid Med Cell Longev. 2019;2019:6435364.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Del Olmo-Aguado S, et al. Plasma rich in growth factors reduces blue light-induced oxidative damage on retinal pigment epithelial cells and restores their homeostasis by modulating vascular endothelial growth factor and pigment epithelium-derived factor expression. Clin Exp Ophthalmol. 2020;48:830-838. Epub 2020/04/29.
   PubMed Web of Science ®Google Scholar
• Suarez-Barrio C, Del Olmo-Aguado S, Garcia-Perez E, et al. Antioxidant role of PRGF on RPE cells after blue light insult as a therapy for neurodegenerative diseases. Int J Mol Sci. 2020;21:1021. Epub 2020/02/04.
   Web of Science ®Google Scholar
• Li R, Du JH, Yao GM, et al. Autophagy: a new mechanism for regulating VEGF and PEDF expression in retinal pigment epithelium cells. Int J Ophthalmol. 2019;12:557–562.
   PubMed Web of Science ®Google Scholar
• Suarez-Barrio C, Del Olmo-Aguado S, Garcia-Perez E, et al. Plasma rich in growth factors enhances cell survival after in situ retinal degeneration. Int J Mol Sci. 2020;21:7442.
   Web of Science ®Google Scholar
• Wu TT, Kung YH. Comparison of anatomical and visual outcomes of macular hole surgery in patients with high myopia vs. non-high myopia: a case-control study using optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2012;250: 327–331. Epub 2011/09/22.
   PubMed Web of Science ®Google Scholar
• Madi HA, Masri I, Steel DH. Optimal management of idiopathic macular holes. Clin Ophthalmol. 2016;10: 97–116. Epub 2016/02/03.
   PubMed Web of Science ®Google Scholar
• Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233:549–554. Epub 1995/09/01.
   PubMed Web of Science ®Google Scholar
• Paques M, Chastang C, Mathis A, et al. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology. 1999;106:932–938. Epub 1999/05/18.
   PubMed Web of Science ®Google Scholar
• Purtskhvanidze K, Frühsorger B, Bartsch S, et al. Persistent full-thickness idiopathic macular hole: anatomical and functional outcome of revitrectomy with autologous platelet concentrate or autologous whole blood. Ophthalmologica 2018;239:19–26. Epub 2017/10/20.
   PubMed Web of Science ®Google Scholar
• Arias J, Hoyos A, Alcántara B. et al. Plasma rich in growth factors for persistent macular hole: a pilot study. Retin Cases Br Rep. 2019;1. Epub 2019/12/31.
   Google Scholar
• Sanchez-Avila RM, Fernandez-Vega Gonzalez A, Fernandez-Vega Sanz A, et al. Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors. Int Med Case Rep J. 2019;12:229–233.
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Mora Cantallops A, Virgili G, et al. Long-term results of autologous plasma as adjuvant to pars plana vitrectomy in the treatment of high myopic full-thickness macular holes. Eur J Ophthalmol. 2020;1120672120960340. Epub 2020/09/29.
   Web of Science ®Google Scholar
• Anitua E, Murias-Freijo A, Alkhraisat MH, et al. Clinical, radiographical, and histological outcomes of plasma rich in growth factors in extraction socket: a randomized controlled clinical trial. Clin Oral Invest. 2015;19:589–600. Epub 2014/07/08.
   PubMed Web of Science ®Google Scholar
• Anitua E, Prado R, Orive G. Bilateral sinus elevation evaluating plasma rich in growth factors technology: a report of five cases. Clin Implant Dent Relat Res. 2012;14: 51–60. Epub 2010/07/16.
   PubMed Web of Science ®Google Scholar
• Torres J, Tamimi F, Martinez PP, et al. Effect of platelet-rich plasma on sinus lifting: a randomized-controlled clinical trial. J Clin Periodontol. 2009;36:677–687, Epub 2009/07/01.
   PubMed Web of Science ®Google Scholar
• Gilli SC, do Valle Oliveira SA, Saad ST. Autologous platelet gel: five cases illustrating use on sickle cell disease ulcers. Int J Low Extrem Wounds. 2014;13:120–126.
   PubMed Web of Science ®Google Scholar
• Sánchez M, Delgado D, Garate A, et al. PRP injections in orthopaedic surgery: why, when and how to use PRP dynamic liquid scaffold injections in orthopaedic surgery. In: Tutar Y, Tutar L, editors. Plasma Medicine—Concepts and Clinical Applications. IntechOpen: London, UK. 2018.
   Google Scholar
• Sánchez M, Albillos J, Angulo F, et al. Platelet-rich plasma in muscle and tendon healing. Oper Tech Orthop. 2012;22:16–24.
   Google Scholar
• Kraeutler MJ, Garabekyan T, Mei-Dan O. The use of platelet-rich plasma to augment conservative and surgical treatment of hip and pelvic disorders. Muscles Ligaments Tendons J. 2016;6: 410–419. Epub 2017/01/10.
   PubMedGoogle Scholar
• Navarro RM, Pino A, Martinez-Andres A, et al. The effect of plasma rich in growth factors combined with follicular unit extraction surgery for the treatment of hair loss: a pilot study. J Cosmet Dermatol. 2018;17:862–873. Epub 2017/10/28.
   PubMed Web of Science ®Google Scholar
• Jiménez Gómez N, Pino Castresana A, Segurado Miravalles G, et al. Autologous platelet-rich gel for facial rejuvenation and wrinkle amelioration: a pilot study. J Cosmet Dermatol. 2018; Epub 2018/11/20.
   PubMed Web of Science ®Google Scholar
• Anitua E, Pino A. The management of postsurgical wound complications with plasma rich in growth factors: a preliminary series. Adv Skin Wound Care. 2020;33: 202–208. Epub 2019/12/04.
   PubMed Web of Science ®Google Scholar
• Díaz-Ley B, Cuevast J, Alonso-Castro L, et al. Benefits of plasma rich in growth factors (PRGF) in skin photodamage: clinical response and histological assessment. Dermatol Ther. 2015;28:258–263. Epub 2015/04/14.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Fuente M, Ferrando M, et al. Biological effects of plasma rich in growth factors (PRGF) on human endometrial fibroblasts. Eur J Obstet Gynecol Reprod Biol. 2016;206:125–130. Epub 2016/10/04.
   PubMed Web of Science ®Google Scholar
• Sánchez M, Anitua E, Delgado D, et al. Platelet-rich plasma, a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration. Expert Opin Biol Ther. 2017;17:197–212. Epub 2016/11/16.
   PubMed Web of Science ®Google Scholar
• Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol. 2007;44: 3901–3908. Epub 2007/09/05.
   PubMed Web of Science ®Google Scholar